Physician profile
Kenneth Starr
NPI 1861431595
$63,695.88
in general payments reported to CMS, 2019-2025
7 companies · $9,707 in 2025
The $9,707 reported for 2025 was more than what 95% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $42.50 · 2021: $18K · 2022: $10K · 2023: $14K · 2024: $11K · 2025: $9,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $3,372 · Food and Beverage: $1,709 · Consulting Fee: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,260.00 |
| Travel and Lodging | $3,371.81 |
| Food and Beverage | $1,709.29 |
| Consulting Fee | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $62,844.32 | 2019-2025 | Vivitrol, Vivitrol |
| Indivior INC. | $467.40 | 2019-2025 | Sublocade |
| Braeburn INC. | $173.73 | 2023-2025 | Brixadi |
| Gilead Sciences, INC. | $77.75 | 2019 | |
| Uswm, LLC | $72.49 | 2023-2024 | Lucemyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.55 | 2019 | |
| Allergan, INC. | $24.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.